Our understanding of that landmark trial, the Women’s Health Initiative (WHI), continues to evolve. Data from younger women in the WHI, in addition to findings from the ELITE trial, suggest a favorable benefit/risk balance when menopausal hormone therapy is started within 10 years of the menopause transition or at age ≤ 60 years. As a result, the clinical guidelines for menopausal hormone therapy have changed. In addition, the SWAN study has provided us with a deeper understanding of women’s experiences during the menopause transition.